Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952297 · ClinicalTrials.gov registry record · Phase 2
A Novel Wearable Device to Improve Sleep Quality
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT05952297: Completed Phase 2 study, sponsored by University of Utah.
NCT05952297 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05952297, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of the study is to help determine if a wearable sleep wellness device improves sleep among adults with insomnia. This study will enroll a total of 60 participants for this remotly conducted study and randomize 1:1 for treatment and control. Aim 1 of the study is to test the effects of the sleep wellness device compared to a placebo device on sleep after 28 days of use. Aim 2 of the study is to test the longer term effects of the sleep wellness device at 3 month follow-up.
Primary Outcome
The insomnia severity index (ISI) is a self-report item of insomnia symptoms that is well correlated with insomnia diagnoses, with higher scores being worse insomnia. Scores range from 0-28.
Interventions
- DEVICE Sleep Wellness Device (BeCurie)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 2 |
What the finished NCT05952297 record still lists
NCT05952297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which Sleep Wellness Device (BeCurie) is the first listed.
NCT05952297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05952297 about?
NCT05952297 is a clinical study titled "A Novel Wearable Device to Improve Sleep Quality". The purpose of the study is to help determine if a wearable sleep wellness device improves sleep among adults with insomnia. This study will enroll a total of 60 participants for this remotly conducted study and randomize 1:1 for treatment and control. Aim 1 of the study is to test the effects of t...
What is the current status of trial NCT05952297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2023-09-01. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT05952297?
The interventions under investigation include: Sleep Wellness Device (BeCurie) (DEVICE).
Who is sponsoring clinical trial NCT05952297?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05952297's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI